Brief: Cereno Scientific Submits Trial Protocol To U.S. FDA
10/11/2025 06:49
Nov 10 (Reuters) - Cereno Scientific AB CRNOSb.ST: SUBMITS PHASE IIB TRIAL PROTOCOL FOR CS1 IN PULMONARY ARTERIAL HYPERTENSION (PAH) TO U.S. FDA ANTICIPATES FDA CLEARANCE FOR TRIAL IN H1 2026 PHASE IIB TRIAL PLANNED TO BEGIN DURING H1 2026 Source text: ID:nWkr1D1JHL Further company coverage: CRNOSb.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cereno Scientific AB
See all newsBrief: Cereno Scientific Carries Out Directed Share Issue Of SEK 60 Mln
Brief: Cereno Scientific Strengthens Patent Protection For Cs1 In Canada
Sweden's Cereno Scientific Q1 net loss widens amid clinical development
Brief: Cereno Scientific Q1 Loss After Financial Items SEK 28.6 Mln
Brief: Cereno Enters Collaboration With PHA Europe & Global